

Comparison of claims data on hospitalization rates and repeat procedures in patients receiving a bowel preparation prior to colonoscopy

SAGE Open Medicine

Volume 5: 1–8

© The Author(s) 2017

Reprints and permissions:

sagepub.co.uk/journalsPermissions.nav

DOI: 10.1177/2050312117727999

journals.sagepub.com/home/smo

Lisa E Young¹, Naomi C Sacks^{2,3}, Philip L Cyr^{2,4}, Abhishek Sharma^{2,5}
and David N Dahdal¹

Abstract

Objectives: To evaluate outcomes of colorectal screening using sodium picosulfate and magnesium citrate compared with other prescription bowel-preparation agents. Primary endpoints were rates of procedure-associated hospitalizations, diagnosis at hospitalization, and rates of early repeat screenings.

Methods: This retrospective cohort study identified patients using the Truven Health Analytics MarketScan databases, which contain fully adjudicated, de-identified, medical- and prescription-drug claims, as well as demographic and enrollment information for individuals with commercial, Medicaid, and Medicare supplemental insurance coverage. Patients who had a colonoscopy or sigmoidoscopy over a 3-year period were identified using *International Classification of Diseases Clinical Modification* procedure codes, recorded on claims from physicians and facilities. First, screening colonoscopy was identified for each patient, and the study was limited to those patients who could be observed for ≥ 6 months before and 3 months after the screening procedure. Total number of hospitalizations and rates of early repeat screenings were evaluated for all patients who received sodium picosulfate and magnesium citrate and compared with those who received other bowel-preparation agents. Individual prescription medications that could affect the outcome of the cleansing agent were identified; further evaluations were made to establish whether patients had comorbid conditions, such as chronic kidney disease, cardiovascular disease, or psychiatric illness. Statistical methods included descriptive statistics, two-tailed *t*-tests, and multivariate logistic regression.

Results: A total of 566,628 procedures were identified in the MarketScan databases and included in the study. Sodium picosulfate and magnesium citrate performed well in terms of safety outcomes, with no hospitalizations due to diagnosis of hyponatremia, dehydration, or other fluid disorders in the 10 days after procedure. Early repeat rates among sodium picosulfate and magnesium citrate patients were comparable with rates observed for all other cleansing agents.

Conclusion: Outcomes of colorectal screening using sodium picosulfate and magnesium citrate were not significantly different compared with other prescription bowel-preparation agents.

Keywords

Bowel preparation, colonoscopy preparation, colorectal cancer screening, health economics, health insurance, outcomes research, Prepopak, sodium picosulfate and magnesium citrate

Date received: 16 June 2017; accepted: 28 July 2017

Introduction

Colorectal cancer (CRC) is currently the fourth most common cancer in the United States.^{1–3} The incidence is higher in

men, and compared with many other forms of cancer, CRC has a relatively high mortality rate with a 5-year survival rate

¹Ferring Pharmaceuticals Inc., Parsippany, NJ, USA

²Precision Health Economics, Boston, MA, USA

³School of Medicine, Tufts University, Boston, MA, USA

⁴University of North Carolina at Charlotte, Charlotte, NC, USA

⁵Department of Global Health and Center for Global Health & Development, School of Public Health, Boston University, Boston, MA, USA

Corresponding author:


Lisa E Young, Ferring Pharmaceuticals Inc., 100 Interpace Parkway, Parsippany, NJ 07054, USA.

Email: lisa.young@ferring.com



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons

Attribution-NonCommercial 4.0 License (<http://www.creativecommons.org/licenses/by-nc/4.0/>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).



Supplementary Figure 1. Colorectal cancer incidence and number of deaths in the United States from 1992 to 2013. Adapted from the National Cancer Institute, SEER Program.³ CRC: colorectal cancer; SEER: Surveillance, Epidemiology and End Results.

estimated at 65.1% (Supplementary Figure 1).^{1–3} While the median age at CRC diagnosis is 68 years with a disproportionate gender distribution, regular screening of at-risk patients improves the odds of detecting CRC at an early stage.⁴ Colonoscopy is the most sensitive method for the detection of CRC and adenomatous polyps, which also allows the removal of precancerous lesions to prevent further development and is thus the gold standard for CRC screening.^{5,6}

Adherence to colonoscopy screening guidelines with adequate bowel preparation that allows full visibility of the colon—defined as the ability to identify lesions >5 mm^{7–9}—is associated with decreased CRC incidence and mortality rates.^{10,11} Adequate bowel preparation is critical not only for safe and effective colonoscopy screening,^{12,13} but is also associated with a significant decrease in the adenoma miss rates, early repeat screenings, hospitalizations, and other high-cost events.^{13–17} While outcomes have a strong association with successful preparation, a recent retrospective analysis assessing degree of bowel cleansing in both inpatients and outpatients undergoing colonoscopy found that inadequate cleansing was recorded in 11.2% of the patients.¹⁸ No significant difference was observed between inpatients and outpatients.

An adequate bowel preparation involves the use of a cleansing agent prescribed prior to the procedure, such as high-volume (HV) bowel-preparation products (i.e. 4-L polyethylene glycol (PEG) solutions), low-volume (LV) products (e.g. 2-L PEG solutions), or other over-the-counter (OTC) products (e.g. magnesium citrate).

Adverse events (AEs) following ingestion of bowel preparations are uncommon, but can be serious.¹⁹ Regarding the safety of colonoscopy and bowel preparation, a recent study found the rate of AEs to be low even under severe conditions, although the majority of these patients would not have been coded for a screening procedure.²⁰ HV products have

been associated with AEs, such as nausea, vomiting, bloating, and cramps, and typically require patients to consume up to 4 L of a solution with an often unpalatable salty taste. As a result, patients may be less tolerant of HV agents and at greater risk for inadequate preparation. LV products are reportedly easier for the patient to consume and are generally well tolerated with similar or better cleansing quality compared with HV agents.^{12,21,22} Documented AEs with LV preparations include dehydration, hyponatremia, electrolyte imbalances, and in rare cases, kidney damage.²³

Prepopik® (Ferring Pharmaceuticals Inc., Parsippany, NJ, USA) is a LV sodium picosulfate and magnesium citrate (P/MC) bowel-preparation agent approved for colon cleansing prior to colonoscopy or sigmoidoscopy in adults.²⁴ For each bowel preparation, the patient is required to consume the drug dissolved in 5 oz of water at two different times, followed by 40 or 24 oz, respectively, of a clear liquid of the patient's choice, to be consumed within 5 h.²⁴ In previous clinical trials, bowel cleansing using P/MC preparations have been demonstrated to be both safe and effective with the potential to increase patient adherence to colorectal screening guidelines.^{25–27}

The rationale for this study was based on a misconception of efficacy concerning CRC procedures driven by the use of various bowel preparation scales in clinical trials. The objectives were to evaluate real-world clinical outcomes of CRC screening by comparing P/MC with different prescription bowel-preparation agents, including the incidence of early repeat-screening events and hospitalization rates, and assessment of the evidence in a retrospective analysis.

Methods

Study design

Using employer-based health insurance claims filed between 1 January 2012 and 30 June 2014, this retrospective cohort study evaluated outcomes of colorectal screening in patients using P/MC compared with patients who used other cleansing agents. The patients were identified using the Truven Health Analytics MarketScan databases (now part of IBM Watson Health), which contain fully adjudicated, de-identified, medical- and prescription-drug claims, as well as demographic and enrollment information for individuals with commercial, Medicaid, or Medicare supplemental insurance coverage. Colonoscopies and sigmoidoscopies were identified using the *International Classification of Diseases, 9th revision, Clinical Modification* (ICD-9-CM) procedure codes, recorded on claims from physicians and facilities (Supplementary Table 1); the claims data for this study were filed before the transition to ICD-10 on 1 October 2015. Because physicians performing these procedures can file claims separately from the facilities where procedures are performed, we grouped all claims occurring within 1 day of each other and considered them as one event. All patient data

Supplementary Table 1. Codes used to identify colonoscopies and sigmoidoscopies.

ICD-9-CM codes	
Colonoscopy	44397, 45355, 45391, 45392, G0105, G0121, 44388, 44389, 44390, 44391, 44392, 44393, 44394, 45378, 45379, 45380, 45381, 45382, 45383, 45384, 45385, 45386, 45387, 45330, 45331, 45332, 45333, 45334, 45335, 45337, 45338, 45339, 45340, G0104
Sigmoidoscopy	4522, 4523, 4524, 4525, 4542, 4543
Screening procedure	
Procedure modifier	33, PT
or	4522, 4524, 4523, 44355, 45391, 45392, G0105, G0121, G0104, 45377-45388, 44387-44395
Procedure code	
Diagnostic procedure	All other

ICD-9-CM: *International Classification of Diseases, 9th revision, Clinical Modifications.*

Table 1. Classification of bowel preparations.

LV products	HV products	Other bowel preparations
Prepikik ^a	Colyte ^b	OsmoPrep ^c
HalfLyte ^d	GaviLyte TM ^e	Visicol ^c
MoviPrep ^c	GoLYTELY ^d	
Suclear ^d	NuLYTELY ^d	
Suprep ^d	Trilyte ^f	

HV: high-volume; LV: low-volume.

^aFerring Pharmaceuticals Inc., Parsippany, NJ.

^bPharmascience Inc., Montreal, QC, Canada.

^cSalix Pharmaceuticals, Inc., Raleigh, NC.

^dBraintree Laboratories, Inc., Braintree, MA.

^eGAVIS Pharmaceuticals, Somerset, NJ.

^fWallace Pharmaceuticals Inc., Somerset, NJ.

were tracked for 9 months, with patients required to have had no colonoscopy or sigmoidoscopy in the 6 months prior to the initial screening and repeat screenings defined as secondary screenings that occurred ≤ 3 months after the initial screening.

The bowel-preparation agent used with each procedure was identified through pharmacy records of the closest filled prescription within 90 days prior to the colonoscopy or sigmoidoscopy. All solution-based cleansing agents were classified as either HV (≥ 4 -L solution) or LV (< 4 -L solution), based on their approved labeling and directions for use (Table 1). Tablet-based agents (OsmoPrep[®] and Visicol[®], Salix Pharmaceuticals, Inc., Raleigh, NC, USA) were categorized as “other bowel preparations,” and OTC products were not included in this analysis.

Inclusion/exclusion criteria

The purpose of this study was to focus on average-risk patients. Key inclusion criteria were age ≥ 18 years, at least one identified claim for a colonoscopy or sigmoidoscopy within the study period, at least one prescription for a cleansing agent filled within 90 days before the procedure, and the availability of medical and pharmacological data for each patient (≥ 6 months prior and ≥ 3 months after the procedure).

Supplementary Table 2. ICD-9 codes used to indicate high-risk patients.³⁰

Code	Diagnosis
V10.05	Personal history of malignant neoplasm of large intestine high-risk screening code
V10.06	Personal history of malignant neoplasm of rectum, recto sigmoid junction, and anus high-risk screening code
V12.72	Personal history of adenomatous colonic polyps high-risk screening code
V16.0	Family history of malignant neoplasm of gastrointestinal tract first degree relative-sibling, parent, child high-risk screening code
V18.51	Family history, adenomatous colonic polyps high-risk screening code
V76.41	Special screening for malignant neoplasms of rectum
V76.51	Special screening for malignant neoplasms of colon
V84.09	Genetic susceptibility to other malignant neoplasm not covered by all payers

ICD-9: *International Classification of Diseases, 9th revision.*

Data with no identifiable prescription for a cleansing agent (e.g. use of OTC products or physician samples) prior to the procedure were excluded from the analysis. Patient health status was estimated using the Charlson Comorbidity Index (CCI),²⁸ which is widely used as a measure of patient health status that summarizes comorbidities of patients based on the diagnosis codes found in administrative claims data, with higher scores indicative of poorer health.

To minimize potentially confounding comorbidities, patients determined to be at high risk for CRC based on medical claims were excluded. These high-risk patients were identified through the colonoscopy procedure code G0105 and a selection of ICD-9 codes (Supplementary Table 2).^{29,30}

Study measures

Patient demographics (i.e. age, sex, geographic region, and risk status) and cleansing agent used for each procedure were

Supplementary Table 3. Codes used to identify hospitalizations for selected conditions.

Condition	ICD-9 codes
Colon cancer	152, 1521, 1522, 1523, 1528, 1529, 1530, 1531, 1532, 1533, 1534, 1535, 1536, 1537, 1538, 1539, 1540, 1541, 1542, 1543, 1548, 1974, 2307, 209, 20901, 20902, 20903, 20910, 20911, 20912, 20913, 20914, 20915, 20916, 20917, 20926, 20927, 2094, 20941, 20942, 20943, 2095, 20951, 20952, 20953, 20954, 20955, 20956, 20957, 20967, 2113, 2114, 2303, 5564
Diverticulosis	5621, 56211, 56212, 56213, 7513
Injury	8634, 86341, 86342, 86343, 86344, 86346, 86349, 8635, 86351, 86352, 86353, 86354, 86356, 86359, 936
Hyponatremia	276.0, 276.1
Dehydration	276.50, 276.51, 276.52
Other fluid or electrolyte disorder	276.2, 276.3, 276.4, 276.61, 276.69, 276.7, 276.8, 276.9

ICD-9: *International Classification of Diseases, 9th revision.*

collected and used to stratify the results. Primary endpoints were rates of procedure-associated hospitalizations, diagnosis at hospitalization (i.e. CRC vs non-CRC), and rates of early repeat screenings. Hospitalizations were defined as any hospital admission that occurred within 10 days of a procedure. Fluid levels are a particular concern for LV agents, and non-CRC diagnoses were defined as those directly indicative of product safety that could have been associated with the procedure (i.e. diverticulitis, hyponatremia, dehydration, and other fluid or electrolyte disorders), based on principal discharge diagnosis code (Supplementary Table 3). The total number of hospitalizations and the proportion of non-CRC hospitalizations were compared between patients who received P/MC and those who used other LV products, HV products, or other bowel-preparation agents.

On the recommendation from the US Multi-Society Task Force (MSTF) of CRC, patients with CRC should undergo a colonoscopy within 3–6 months after surgery (for a duration of 2–3 years). For patients who have undergone curative resection of either CRC or rectal cancer, the MSTF recommends surveillance colonoscopy 1 year after surgery.³¹ In this study, early repeat screenings were defined as repeat colonoscopies or sigmoidoscopies scheduled within 90 days of a previous procedure. The rates of early repeat screenings were evaluated for all patients who received P/MC and compared with those who received other LV products, HV products, or other prescription bowel-preparation agents. Individual prescription medications that could affect the outcome of the cleansing agent were identified, including those that affect renal function (e.g. loop and thiazide diuretics) and those associated with hypokalemia or hyponatremia (e.g. cardiac glycosides and corticosteroids). Further evaluations were made to establish whether patients had comorbid conditions, such as chronic kidney disease, cardiovascular disease, or psychiatric illness.

Statistical methods

Patient demographics, patient health status, and presence of repeat procedures and associated hospitalizations were summarized using descriptive statistics, whereas significance of

subgroup differences was evaluated using chi-square test. Multivariate logistic regression was used to evaluate the association between each bowel-preparation group and outcome, and the likelihood of an early repeat screening or hospitalization, with adjustment for age, sex, geography, and CCI score. These analyses were conducted to evaluate whether the rates of early repeat screenings were significantly different for P/MC compared with other agents.

Results

Patient population

Out of 1,329,751 screenings of de-identified patients in the MarketScan databases, a total of 566,628 procedures were deemed eligible to be included in the study (Table 2). A majority of these procedures were performed using LV preparations defined as “other LV” agents (69.0%), followed by HV agents (21.9%), P/MC (5.9%), and other agents (3.2%). Mean age for all patients was 56.4 years (standard deviation (SD), 10.9), with a slightly higher proportion of women than men (53.5% vs 46.5%, respectively). The patient population who used P/MC was slightly younger than average (mean age, 55.1 years; SD, 10.6; $p < 0.0001$), with a larger proportion of female patients (58.2%; $p < 0.0001$).

Mean CCI scores for the total study population were low (0.41; SD, 0.97), indicating that patients were healthy, with a relatively low overall comorbidity burden (Table 2). P/MC patients were healthier, with a lower comorbidity burden and lower mean CCI scores (0.36; SD, 0.89), compared with all others (0.41; SD, 0.97; $p < 0.0001$). Patients who received P/MC were generally prescribed cardiovascular medications at lower rates compared with the mean overall rate among all patient groups, including angiotensin-converting enzyme inhibitors (14% vs 16.3%; $p < 0.0001$), loop diuretics (2% vs 3.1%; $p < 0.0001$), beta blockers (13% vs 14.8%; $p < 0.0001$), calcium channel blockers (9% vs 10.5%; $p < 0.0001$), and statins (27% vs 27.8%; $p < 0.0001$). Other classes of medication, including psychiatric medications, were prescribed at similar rates across patients using all bowel-preparation agents.

Table 2. Procedures and patient characteristics.

	Bowel-preparation products				
	P/MC	Other LV ^a	HV	Other	All agents
Number of procedures	33,574	391,063	123,853	18,138	566,628
Mean age, years (SD)	55.1 (10.6)	56.0 (10.8)	58.1 (11.2)	55.0 (10.7)	56.4 (10.9)
Female, %	58.2	53.3	51.4	64.1	53.5
Mean CCI score (SD)	0.36 (0.89)	0.39 (0.95)	0.47 (1.06)	0.36 (0.89)	0.41 (0.97)
Geographic region, %					
Northeast	23.6	19.8	15.7	18.9	19.1
Midwest	11.6	19.1	23.7	19.2	19.7
South	49.8	41.1	27.4	43.8	38.9
West	13.0	18.0	31.1	15.3	20.5
Other	2.0	1.6	2.2	2.8	1.8

P/MC: sodium picosulfate and magnesium citrate; LV: low-volume; HV: high-volume; SD: standard deviation; CCI: Charlson Comorbidity Index.

^aLV agents, except P/MC.

Table 3. Procedures and hospitalizations within 10 days of screening.

Procedures and Hospitalizations, n (%)	Bowel-preparation products				
	P/MC	Other LV ^a	HV	Other	All agents
Total procedures	33,574 (5.9)	391,063 (69.0)	123,853 (21.8)	18,138 (3.2)	566,628 (100)
Total hospitalizations ^b	154 (0.5)	2298 (2.5)	888 (6.4)	93 (0.5)	3433 (0.6)
CRC-related ^c	27 (17.5)	338 (14.7)	129 (14.5)	11 (11.8)	505 (14.7)
Non-CRC-related ^c	127 (82.5)	1960 (85.3)	759 (85.5)	82 (88.2)	2928 (85.3)
Diverticulitis ^d	10 (7.9)	199 (10.1)	56 (7.4)	8 (9.8)	273 (9.3)
Hyponatremia ^d	0 (0.0)	13 (0.7)	1 (0.1)	1 (1.2)	15 (0.5)
Dehydration ^d	0 (0.0)	7 (0.4)	1 (0.1)	0 (0.0)	8 (0.3)
Other fluid or electrolyte disorders ^d	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Other ^d	117 (92.1)	1741 (88.8)	701 (92.4)	73 (89.0)	2632 (89.9)

P/MC: sodium picosulfate and magnesium citrate; LV: low-volume; HV: high-volume; CRC: colorectal cancer.

^aLV agents, except P/MC.

^bPercentage of number of procedures by agent.

^cPercentage of total hospitalizations by agent.

^dPercentage of non-CRC-related total hospitalizations by agent.

Efficacy/safety outcomes

Hospitalizations. Out of the 566,628 procedures in the study, a total of 3433 (0.6%) were associated with a hospitalization within 10 days of screening, of which 505 cases (14.7%) were for diagnoses of CRC, and the remaining 2928 cases (85.3%) were admissions for any cause other than CRC (Table 3). The rates of non-CRC hospitalization per 1000 screens were 3.78 for P/MC, 5.01 for other LV, and 6.13 for HV preparations.

While non-CRC admissions potentially related to the use of a cleansing agent (i.e. hyponatremia, dehydration, or other fluid/electrolyte disorders) were generally infrequent in the 10 days following the procedures ($n=23/2928$ total non-CRC hospitalizations; 0.8%), the majority of these patients used other LV agents ($n=20/23$), whereas no admissions were observed for P/MC patients. All other non-CRC admissions were for diagnoses unrelated to CRC screening.

While patients who used P/MC were hospitalized to a lesser degree in the 10 days following a procedure compared with all bowel-cleansing agents (4.6 vs 6.1 per 1000 screenings, respectively), a larger proportion of P/MC patients were hospitalized with a diagnosis of CRC compared with all agents ($n=27/154$ (17.5%) vs $n=505/3433$ (14.7%) hospitalizations, respectively).

Early repeat screenings. A total of 4359 (0.8%) screenings were identified as early repeat events, defined as any repeat screening occurring within 90 days of a previous procedure (no code was implemented), with the greatest early repeat rate associated with HV preparations (0.9%; Table 4).

Adjusted analyses

Adjusted analyses, controlling for age, sex, geographic location, and health status, showed that all bowel-cleansing agents

Table 4. Early repeat-screening events.

	Bowel-preparation products				
	P/MC	Other LV ^a	HV	Other	All agents
Number of procedures	33,574	391,063	123,853	18,138	566,628
Repeat screenings, <i>n</i> (%)	269 (0.77)	2859 (0.73)	1080 (0.87)	151 (0.83)	4359 (0.77)

P/MC: sodium picosulfate and magnesium citrate; LV: low-volume; HV: high-volume.

^aLV agents, except P/MC.

Table 5. Odds ratio estimates.

Comparison	Odds ratio	<i>p</i> -value
Early repeat screenings, OR (95% CI)		
LV ^a versus P/MC	1.103 (0.973, 1.251)	0.1266
HV versus P/MC	0.911 (0.793, 1.047)	0.1914
Other versus P/MC	0.958 (0.783, 1.173)	0.6801
All LV versus HV	0.858 (0.799, 0.921)	<0.0001
Age		
LV ^a	1.008 (1.004, 1.011)	<0.0001
Other	1.014 (1.004, 1.023)	0.0051
HV	1.006 (1.001, 1.01)	0.0297
All LV	1.007 (1.004, 1.009)	<0.0001
CCI		
LV ^a	1.287 (1.257, 1.319)	<0.0001
Other	1.263 (1.174, 1.358)	<0.0001
HV	1.238 (1.194, 1.283)	<0.0001
All LV	1.27 (1.245, 1.297)	<0.0001
Sex		
LV ^a	0.982 (0.915, 1.054)	0.6169
Other	1.189 (0.972, 1.454)	0.0918
HV	1.017 (0.913, 1.133)	0.7606
All LV	0.98 (0.922, 1.042)	0.5192
CRC hospitalizations, OR (95% CI)		
P/MC versus LV ^a	0.915 (0.744, 1.124)	0.397
P/MC versus Other	1.066 (0.753, 1.508)	0.7187
P/MC versus HV	0.92 (0.734, 1.153)	0.4678
All LV versus HV	0.958 (0.862, 1.065)	0.43

OR: odds ratio; CI: confidence interval; P/MC: sodium picosulfate and magnesium citrate; HV: high-volume; LV: low-volume; CCI: Charlson Comorbidity Index; CRC: colorectal cancer.

^aLV agents, except P/MC.

compared favorably with each other. While estimates on repeat-procedure rates for patients who used P/MC were not significantly different compared with other LV products (odds ratio (OR), 1.103; 95% confidence interval (CI), 0.973–1.251; $p=0.1266$), repeat-procedure rates for P/MC and other LV agents were significantly lower when compared with HV bowel-preparation products (OR, 0.858; 95% CI, 0.799–0.921; $p<0.0001$; Table 5). In these analyses, the only factors significantly associated with higher rates of early repeat screenings were older age (all estimates, $p<0.03$) and poor health status (all estimates, $p<0.0001$). In adjusted analyses that compared P/MC with other LV agents and controlled for

age, sex, and health status, no significant differences were detected in CRC hospitalizations within 30 days of screening agents (Table 5).

Discussion

In this retrospective study of real-world clinical outcomes associated with colonoscopy and sigmoidoscopy procedures, we found that P/MC compared similarly with other commonly used LV/HV agents and standard-of-care bowel-cleansing preparations. P/MC performed well in terms of safety outcomes, with no hospitalizations due to a diagnosis of hyponatremia, dehydration, or other fluid disorders in the 10 days after a procedure, and the early repeat rate among P/MC patients was comparable with the rate observed for all other bowel preparations.

Previous studies have suggested that the timing of the preparation could influence the quality of the cleansing and the outcome of the procedure.^{22,32} According to these studies, a shorter preparation-to-colonoscopy interval may be more favorable than a longer interval, which leads to more efficacious bowel cleansing. The outcome associated with a shorter preparation-to-colonoscopy interval^{22,32} further suggests that preparations that are easier to consume may have an inherent advantage.

We found that patients using P/MC had fewer concomitant medications, which could be indicative of general health status, accompanied by a lower rate of hospitalization, a higher comparative proportion of CRC diagnoses, and no significant differences in post-screen CRC-hospitalization rates. The results could be associated with explicit patient characteristics, such as the relative younger age and higher proportion of female patients within this population.

While we have established a large sample size with a rigorous identification of measures and outcomes, a major limitation of the study is that we used data that reflect experiences of relatively younger individuals (mean age, 56.4 years) with insurance and as such, may not be generalizable to all patients who undergo colorectal screening. The short follow-up window should also be considered a limitation, as rates of repeat screenings and CRC diagnoses may be more accurate when observed over an extended period. However, it remains unclear how hospitalizations that occur ≥ 3 months after a screening should reflect on the outcome and success of a procedure. It may also be considered a limitation that

canceled or rescheduled procedures would not show up in claims data, as the claims only reflect services rendered. Neither did this analysis include OTC agents, which are the majority of cleansing agents used prior to colonoscopy. It is also a significant limitation that split-dose preparations (standard of care) cannot be evaluated in cross-group comparisons using claims-based analysis. However, it is likely that the repeat screen rates constitute a mixture of split/non-split dose patients. Another limitation of the claims database is that it is not possible to extrapolate which patient populations were given which products or identify how those products were administered. However, given the large number of patients screened, these factors should be similar among the different agents, and would be factored into the number of patients returning for a repeat screen, despite being given the most appropriate bowel preparation. Finally, the use of claims data may have masked the influence of individual factors on the outcome of the bowel preparations and the subsequent screening procedures.¹¹

While the statistics from the National Cancer Institute have demonstrated a seemingly steady decline of CRC incidence and CRC mortality between 1992 and 2013 among those aged ≤50 years (Supplementary Figure 1), overall CRC incidence and death rates have increased by almost 2% per year within the same time frame.^{2,3} This observation is an indication of an ongoing and unmet need for adequate bowel preparations and more efficient and timely screening procedures. As the median age of the American population is steadily increasing,³³ it has been estimated that costs associated with CRC and the future economic burden to the Medicare program and its beneficiaries will be substantial, further highlighting the importance of adequate colorectal screening preparations.³⁴

Conclusion

The findings presented herein may assist physicians and policymakers in modifying standard-of-care screenings to reduce the negative outcomes associated with inadequate preparations. P/MC and LV products are well tolerated with similar cleansing quality and AEs comparable with those of HV products. Future research may provide further guidance on how the proper use of P/MC, LV, and HV agents, or other bowel-cleansing agents, may increase rates of adequate preparation and subsequent successful screening procedures, as well as reduce rates of hospitalization and early repeat events, ultimately enhancing overall patient care.

Acknowledgements

Editorial support was provided by The Curry Rockefeller Group, LLC, Tarrytown, NY, USA.

Declaration of conflicting interests

L.E.Y. and D.N.D. are employees of Ferring Pharmaceuticals Inc. N.C.S., P.L.C., and A.S. are employees of Precision Health Economics.

Ethical approval

Ethical approval was not sought for this study because this study is based on claims data from Truven Health Analytics MarketScan databases.

Funding

This work was supported by the Ferring Pharmaceuticals Inc.

Informed consent

Informed consent was not sought for this study because this study is based on claims data from Truven Health Analytics MarketScan databases.

References

1. Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. *J Natl Cancer Inst* 2015; 107: djv048.
2. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* 2016; 66: 7–30.
3. Howlader N, Noone AM, Krapcho M, et al. *SEER cancer statistics review, 1975–2013*. Bethesda, MD: National Cancer Institute (NCI), 2016 (Based on November 2015 SEER data submission, posted to the SEER web site).
4. Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. *N Engl J Med* 2013; 369: 1095–1105.
5. Rockey DC, Paulson E, Niedzwiecki D, et al. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. *Lancet* 2005; 365: 305–311.
6. Wong MC, Ching JY, Chan VC, et al. Colorectal cancer screening based on age and gender: a cost-effectiveness analysis. *Medicine* 2016; 95: e2739.
7. Clark BT, Rustagi T and Laine L. What level of bowel prep quality requires early repeat colonoscopy: systematic review and meta-analysis of the impact of preparation quality on adenoma detection rate. *Am J Gastroenterol* 2014; 109: 1714–1723.
8. Lieberman D, Nadel M, Smith RA, et al. Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. *Gastrointest Endosc* 2007; 65: 757–766.
9. Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. *Gastroenterology* 2012; 143: 844–857.
10. Baxter NN, Goldwasser MA, Paszat LF, et al. Association of colonoscopy and death from colorectal cancer. *Ann Intern Med* 2009; 150: 1–8.
11. Iskandar H, Yan Y, Elwing J, et al. Predictors of poor adherence of US gastroenterologists with colonoscopy screening and surveillance guidelines. *Dig Dis Sci* 2015; 60: 971–978.
12. Johnson DA, Barkun AN, Cohen LB, et al. Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the US Multi-Society Task Force on colorectal cancer. *Gastroenterology* 2014; 147: 903–924.
13. Jang JY and Chun HJ. Bowel preparations as quality indicators for colonoscopy. *World J Gastroenterol* 2014; 20: 2746–2750.

14. Chokshi RV, Hovis CE, Hollander T, et al. Prevalence of missed adenomas in patients with inadequate bowel preparation on screening colonoscopy. *Gastrointest Endosc* 2012; 75: 1197–1203.
15. Yadlapati R, Johnston ER, Gregory DL, et al. Predictors of inadequate inpatient colonoscopy preparation and its association with hospital length of stay and costs. *Dig Dis Sci* 2015; 60: 3482–3490.
16. Froehlich F, Wietlisbach V, Gonvers JJ, et al. Impact of colonic cleansing on quality and diagnostic yield of colonoscopy: the European Panel of Appropriateness of Gastrointestinal Endoscopy European multicenter study. *Gastrointest Endosc* 2005; 61: 378–384.
17. Lebowitz B, Kastrinos F, Glick M, et al. The impact of suboptimal bowel preparation on adenoma miss rates and the factors associated with early repeat colonoscopy. *Gastrointest Endosc* 2011; 73: 1207–1214.
18. Rotondano G, Rispo A, Bottiglieri ME, et al. Quality of bowel cleansing in hospitalized patients undergoing colonoscopy: a multicentre prospective regional study. *Dig Liver Dis* 2015; 47: 669–674.
19. Belsey J, Epstein O and Heresbach D. Systematic review: adverse event reports for oral sodium phosphate and polyethylene glycol. *Aliment Pharmacol Ther* 2009; 29: 15–28.
20. Niikura R, Nagata N, Shimbo T, et al. Adverse events during bowel preparation and colonoscopy in patients with acute lower gastrointestinal bleeding compared with elective non-gastrointestinal bleeding. *PLoS ONE* 2015; 10: e0138000.
21. Di Nardo G, Aloï M, Cucchiara S, et al. Bowel preparations for colonoscopy: an RCT. *Pediatrics* 2014; 134: 249–256.
22. Zorzi M, Valiante F, Germana B, et al. Comparison between different colon cleansing products for screening colonoscopy. A noninferiority trial in population-based screening programs in Italy. *Endoscopy* 2016; 48: 223–231.
23. Weir MA, Fleet JL, Vinden C, et al. Hyponatremia and sodium picosulfate bowel preparations in older adults. *Am J Gastroenterol* 2014; 109: 686–694.
24. *Prepopik®* (package insert). Parsippany, NJ: Ferring Pharmaceuticals Inc., 2014.
25. Flemming JA, Vanner SJ and Hookey LC. Split-dose picosulfate, magnesium oxide, and citric acid solution markedly enhances colon cleansing before colonoscopy: a randomized, controlled trial. *Gastrointest Endosc* 2012; 75: 537–544.
26. Rex DK, Katz PO, Bertiger G, et al. Split-dose administration of a dual-action, low-volume bowel cleanser for colonoscopy: the SEE CLEAR I study. *Gastrointest Endosc* 2013; 78: 132–141.
27. Katz PO, Rex DK, Epstein M, et al. A dual-action, low-volume bowel cleanser administered the day before colonoscopy: results from the SEE CLEAR II study. *Am J Gastroenterol* 2013; 108: 401–409.
28. Charlson ME, Pompei P, Ales K, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chron Dis* 1987; 40: 373–383.
29. Department of Health & Human Services (HHS), Centers for Medicare & Medicaid Services (CMS). *CMS Manual System* (Pub 100-04 Medicare Claims Processing, Transmittal 52, Change request 2996). Baltimore, MD: CMS, 2003.
30. Centers for Disease Control and Prevention (CDC). *International Classification of Diseases, 9th revision (ICD-9)*. Atlanta, GA: CDC, 2015.
31. Kahi CJ, Boland CR, Dominitz JA, et al. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectal cancer. *Gastroenterology* 2016; 150: 758–768.
32. Bryant RV, Schoeman SN and Schoeman MN. Shorter preparation to procedure interval for colonoscopy improves quality of bowel cleansing. *Intern Med J* 2013; 43: 162–168.
33. He W, Goodkind D and Kowal P. An aging world: 2015. International population reports, US Census Bureau, US Government Publishing Office, Washington, DC, March 2016.
34. Yabroff KR, Mariotto AB, Feuer E, et al. Projections of the costs associated with colorectal cancer care in the United States, 2000–2020. *Health Econ* 2008; 17: 947–959.